Amal Therapeutics
AMAL Therapeutics is a biotech company focused on developing innovative therapeutic vaccines for cancer treatment. They utilize their proprietary KISIMA® platform to stimulate the immune system and target a broad range of patients, aiming to transform cancer patient prospects with effective therapies that work in synergy with existing treatments.
Industries
Nr. of Employees
small (1-50)
Amal Therapeutics
64 av. de la Roseraie, 1205 Geneva, Switzerland
Patents
Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for treatment of colorectal cancer
US-12220450-B2
View DetailsFusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
US-12220387-B2
View DetailsCombination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine
US-12214048-B2
View DetailsComplex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist
US-12178788-B2
View DetailsFusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
US-11338027-B2
View Details
Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for treatment of colorectal cancer
US-12220450-B2
View DetailsFusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
US-12220387-B2
View DetailsCombination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine
US-12214048-B2
View DetailsComplex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist
US-12178788-B2
View DetailsFusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
US-11338027-B2
View DetailsProducts
ATP128
A clinical-stage protein-based therapeutic vaccine candidate for metastatic colorectal cancer developed from a modular chimeric vaccine platform that combines delivery, adjuvant and multi-antigen elements.
ATP128
A clinical-stage protein-based therapeutic vaccine candidate for metastatic colorectal cancer developed from a modular chimeric vaccine platform that combines delivery, adjuvant and multi-antigen elements.
Services
Partnerships with pharma and diagnostic providers to run early-phase clinical trials and co-develop combination strategies and biomarker integration.
Collaborative preclinical and translational research with academic partners to evaluate mechanisms, combination regimens and candidate selection.
Partnerships with pharma and diagnostic providers to run early-phase clinical trials and co-develop combination strategies and biomarker integration.
Collaborative preclinical and translational research with academic partners to evaluate mechanisms, combination regimens and candidate selection.
Expertise Areas
- Therapeutic vaccine development
- Cancer immunotherapy
- Preclinical in vivo pharmacology
- Translational immunology
Key Technologies
- Protein/peptide vaccine platforms
- Cell-penetrating peptide delivery
- TLR-targeting adjuvant domains
- Multi-epitope vaccine design
News & Updates
December 3-5, Boston, United States, attended by key AMAL team members.
September 8-11, 2024, Washington DC, United States, presentation by Elodie Belnoue.
June 20, 2024, Geneva, Switzerland, presentation by Erika Riva.
AMAL Therapeutics received the Innovation Prize at the 2023 Great Economy Awards, recognizing its contribution to Geneva's economic and scientific landscape.
AMAL Therapeutics was awarded the 2nd Prize at the GHIA in Calgary, among top innovations in healthcare.
December 3-5, Boston, United States, attended by key AMAL team members.
September 8-11, 2024, Washington DC, United States, presentation by Elodie Belnoue.
June 20, 2024, Geneva, Switzerland, presentation by Erika Riva.
AMAL Therapeutics received the Innovation Prize at the 2023 Great Economy Awards, recognizing its contribution to Geneva's economic and scientific landscape.
AMAL Therapeutics was awarded the 2nd Prize at the GHIA in Calgary, among top innovations in healthcare.